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Iron is the most abundant transition metal within the brain, and is vital for a number
of cellular processes including neurotransmitter synthesis, myelination of neurons, and
mitochondrial function. Redox cycling between ferrous and ferric iron is utilized in biology
for various electron transfer reactions essential to life, yet this same chemistry mediates
deleterious reactions with oxygen that induce oxidative stress. Consequently, there is
a precise and tightly controlled mechanism to regulate iron in the brain. When iron is
dysregulated, both conditions of iron overload and iron deﬁciencies are harmful to the
brain. This review focuses on how iron metabolism is maintained in the brain, and how an
alteration to iron and iron metabolism adversely affects neurological function.
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INTRODUCTION
Iron is a fundamental requirement for most known life forms,
and is likely to have played an integral role in the earliest devel-
opment of life on this planet (Russell et al., 1993). Organisms
have evolved to harness the unique chemistry of this highly abun-
dant metal, which make it integral to a vast array of chemical
reactions supporting cell division, oxygen transport and mito-
chondrial function. The iron redox couple mediates the transfer
of single electrons through the reversible oxidation/reduction
reactions of Fe2+ and Fe3+. Iron is a d-block transition metal,
and the unoccupied d-orbitals allow ionic iron (II), iron (III),
and iron (IV) species to form ligands with both small and large
biomolecules via oxygen, nitrogen, and sulfur atoms. The biologi-
cal redox potential and electronic spin state, and thereby reactivity
Abbreviations: AD, Alzheimer’s disease, ADHD, attention deﬁcit hyperactivity
disorder; apo-Tf, apo-transferrin; ATP, adenosine-5′-triphosphate; BBB, blood–
brain barrier; BCEC, brain capillary endothelial cells; BID, brain iron deﬁciency;
cAMP, cyclic adenosine monophosphate; Cp, Ceruloplasmin; CREB, cyclic adeno-
sine monophosphate response element-binding protein; CSF, cerebrospinal ﬂuid;
DMT1, divalent metal transporter 1; Fe, iron; Fe2Tf/holoTf, holo-transferrin;
GWAS, genome-wide association study; HCP1, heme carrier protein 1; HFE,
human hemochromatosis protein; HIF, hypoxia inducible factor; ICP-MS, induc-
tively coupled plasma-mass spectrometry; IRE, iron responsive element; IRP1/2,
iron regulatory proteins 1/2; LMW, low molecular weight; MMSE, mini-mental
state examination; MPTP, methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MRI, mag-
netic resonance imaging; mRNA, messenger RNA; NBIA, neurodegeneration
with brain iron accumulation; NTBI, non-transferrin bound iron; 6-OHDA, 6-
hydroxydopamine; PD, Parkinson’s disease; RLS, restless legs syndrome; ROS,
reactive oxygen species; SN, substantia nigra; STEAP 1-4, six-transmembrane
epithelial antigen of prostate 1-4; TCS, transcranial sonography; Tf, transferrin;
TFR1, transferrin receptor 1; TfR2, transferrin receptor 2; UTR, unstranslated
region; MAPK, mitogen-activated protein kinase; Erk1/2, extracellular signal-
regulated kinase 1/2; GSK-3, glycogen synthase kinase 3; Cdk-5, cyclin-dependent
kinase 5; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; Bcl-2,
B-cell lymphoma 2; NMDA, N-methyl-D-aspartate.
of iron, is determined by the nature of the ligand to which the
species is bound. This conﬁguration, along with the oxidation
state of the iron itself, dictates whether an iron-based biomolecule
is responsible for reactions involving oxygen transport and stor-
age, electron transfer, or oxidation/reduction of other molecules
(Beard, 2001). Reactions involving iron in the body are predom-
inately redox-based, hydrolytic or involve polynuclear complex
formation (Aisen, 2001).
Reliance upon iron for normal physiological function has thus
necessitated a tightly regulated mechanism for ensuring the net
turnover of dietary iron is essentially neutral (Crichton and Ward,
1992). This is especially important for the brain, where some of
the highest concentrations of iron in the body are maintained
(Gerlach et al., 1994). This review will provide an overview of
how brain iron metabolism is regulated, and the consequences of
perturbed iron homeostasis.
IRON UPTAKE, TRANSPORT AND CELLULAR REGULATION
IRON CIRCULATION AND BRAIN UPTAKE
The major iron transporter protein in the body is the 80 kDa gly-
coprotein transferrin (Tf). Each bi-lobar molecule, consisting of
two globular units at the N- and C-terminals has two iron-binding
sites, which form a 4-atom tetradentate ligand via histidine, aspar-
tate, and two tyrosine amino acid residues (Anderson et al., 1987).
Almost all iron exchange and transport within the body is medi-
ated by Tf (Finch and Huebers, 1982), with around 3–4 mg of iron
typically circulating the healthy adult bound to Tf. Two Fe3+ ions
oxidized by a ferroxidase and shunted into the interstitium by fer-
roportin are loaded onto a single Tf unit, and at any one time only
around 30% of all circulating Tf units are occupied (only in cases
of severe iron overload does Tf saturation occur; Aisen, 2001).
Less than 1% of circulating iron is usually non-Tf bound. Non-Tf
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bound iron (NTBI) is handled by a series of low molecular weight
(LMW) ligands including citrate and ascorbate ions, as well as a
possible small contribution from circulating albumin and ferritin
proteins (Breuer et al., 2000) and ATP.
The hydrophobic barricade formed by the blood–brain barrier
(BBB) prevents diffusion of hydrophilic Fe2Tf into the nervous
system, as well as prevent migration of NTBI. Moos et al. (2007)
and Crichton et al. (2011) have recently published comprehensive
pictures of iron trafﬁckingwithin the brain, including uptake from
the periphery. This step, where Fe2Tf is transported across the
BBB through brain capillary endothelial cells (BCECs). Tf-uptake
into BCECs follows an endocytotic mechanism, where circulat-
ing Tf binds to Tf receptors which then internalize. It is a point
of contention as to whether iron export from the endosome is
mediated by the protein divalent metal transporter-1 (DMT1);
conﬂicting reports have either identiﬁed (Burdo et al., 2001) or
failed to identify (Moos and Morgan, 2004) DMT1 in rodent brain
BCECs. An alternative hypothesis has suggested iron becomes
segregated from Tf after liberation from the metal–protein com-
plex in the endosome and is released independently of DMT1
(Moos et al., 2006). During development, when the BBB is not
fully formed, there is a rapid inﬂux of iron most likely stem-
ming from NTBI; the developing rat brain shows a rapid intake
of iron in line with increased expression of transferrin recep-
tor 1 (TfR1) in BCECs, which in turn becomes the major iron
regulatory mechanism once the BBB is sealed, after which iron
intake slows (Taylor and Morgan, 1990). However, brain iron
import is unlikely solely regulated by BCECs, like many other
metabolic pathways redundancies are likely in place in the case one
pathway breaks down. For instance, obstruction of BCEC TfR1
in mice and rats using intravenously administered monoclonal
antibodies did not completely impede brain iron uptake (Ueda
et al., 1993).
A possible alternative mechanism for the uptake of NTBI may
be associated with the expression of ferroportin in the BBB (Wu
et al., 2004) and circulating ferroxidases (enzymes that catalyze
Fe2+ oxidation toFe3+) like ceruloplasmin (Cp;Osaki et al., 1966).
It should be noted, however, that expression of ferroportin in
BCECs has been disputed (Moos and Rosengren Nielsen, 2006). It
is also unclear as to whether iron present in the BCEC endosome
is in fact released into the cytosol. Moos et al. (2007) proposed
that the possible lack of DMT1 is suggestive that the endosome
traverses the BCEC cytosol intact (transcytosis) and releases Fe3+
directly into the brain for distribution to cells.
On the abluminal side of the BCEC astrocytes abut the cell
membrane, forming part of either “neurovascular” or “gliovascu-
lar” units comprising of neurons, astrocytes, and BCECs (Abbott
et al., 2006). Moos et al. (2007) suggested that astrocyte “end feet”
surround the BCEC with a thin layer of interstitial ﬂuid into which
iron is released from endosomal Fe2Tf–TfR1 complexes on the
luminal membrane of the BCEC. Iron is then either re-complexed
by Tf in the brain interstitium, or bound to LMW ligands released
by the astrocyte. While the afﬁnity of iron to small ligands is con-
siderably smaller than that to Tf, it has been suggested that Tf
saturation in the cerebrospinal ﬂuid (CSF) is much higher than
in the periphery, and that a larger proportion of NTBI circulates
the nervous system (Leitner and Connor, 2012). Astrocytes also
provide a source of Cp to ensure any circulating Fe2+ is quickly
oxidized to Fe3+ to prevent unwanted reactive oxygen species
(ROS) production through Fenton chemistry.
CELLULAR IRON TRAFFICKING IN THE BRAIN
Iron is released from Tf into cells via a particularly elegant mech-
anism. TfR1 is a ubiquitously expressed membrane protein with
a dimeric structure and high afﬁnity to Fe2Tf, but at neutral pH,
has a low afﬁnity for apo-Tf (iron-free) so that the unligated Tf
does not act as a competitive inhibitor of holo-Tf (iron-bound)
uptake (Aisen, 2004). The Fe2Tf forms a complex with the TfR1
receptor, which is then endocytosed. A proton pump mechanism
is initiated to lower the pH within the endosome, which causes
a conformational change to both the Fe2Tf and TfR1 units, in
turn resulting in release of the iron from its chaperoning protein
(Hentze et al., 2004). The newly freed Fe3+ is quickly reduced by
the six-transmembrane epithelial antigen of prostate 1-4 (STEAP
1-4), allowing export from the endosome into the cytosol by
DMT1 (DeDomenico et al., 2008). In the acidic endosome, apo-Tf
has a strong afﬁnity for the Tf receptor; this interaction prevents
the degradation of free Tf when the endosome complexes with the
lysosome before exocytosis. During exocytosis the pH returns to
neutral, which causes dissociation of the apo-Tf from the TfR1,
effectively recycling the Tf molecule for further use in iron circula-
tion (Dautry-Varsat et al., 1983). In 1999, a homolog Tf receptor,
TfR2,was identiﬁed (Kawabata et al., 1999),which initially showed
expression only in hepatocytes, duodenal crypt cells, and ery-
throcytes. TfR2 has a 30-fold lower afﬁnity to iron-bound Tf, yet
mutations to the TfR2 gene results in hereditary hemochromatosis
(Camaschella et al., 2000). TfR2 shares 45% amino acid identity
with the ubiquitous TfR1 (Kawabata et al., 1999; Fleming et al.,
2000). Interestingly, TfR2 has also been identiﬁed in dopamin-
ergic neurons, and has been suggested to play a role in Fe2Tf
translocation to mitochondria (Mastroberardino et al., 2009).
Neurons express both TfR1 and DMT1 (Burdo et al., 2001),
and therefore uptake iron via a receptor-mediated endocytotic
mechanism (Figure 1), though it is likely that a small minor-
ity of iron uptake is sourced from NTBI in vivo. Astrocytes are
devoid of TfR1, and NTBI is most likely their major iron source
(Moos and Morgan, 2004). Oligodendrocytes, which require iron
for myelin synthesis (see below; Connor and Menzies, 1998) also
import iron through a mechanism independent of TfR1. Two
noteworthy hypotheses have been proposed to explain how the
comparatively high need for iron by oligodendrocytes is regulated
without the major iron import mechanism present. Firstly, iron
passes into the cytosol complexed with LMW ligands. Iron is then
incorporated into Tf produced within the oligodendrocyte itself,
where it is either used immediately or sequestered in ferritin for
storage (Moos et al., 2007). Tf is not secreted by the oligodendro-
cyte itself (de Arriba Zerpa et al., 2000), presenting a fairly unique
closed environment of iron regulation in what is predominately
otherwise an intertwined regulatory system.
Once inside the cell, iron can follow multiple pathways depen-
dent on need. Ferritins are responsible for iron storage and play an
integral role in iron homeostasis, and are rarely saturated due to
their large capacity for thousands of individual Fe3+ ions (Theil,
2004). Numerous other cytosolic proteins require iron for a variety
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FIGURE 1 | Neuronal iron uptake and export. Iron is imported into the cell
either as low molecular weight complexes with citrate/ATP, or via transferrin
receptor (TfR1)-mediated endocytosis (1). Export of iron from the endosome
via divalent metal transporter-1 (DMT-1) directly contributes to the labile iron
pool (2), which constitutes the available iron content of the neuron and is
regulated by cellular metal sensing and iron-binding protein expression,
including ferritin, which is the major iron storage protein in neurons (3). Export
of iron from neurons is regulated by intramembrane ferroportin, which is
stabilized via a mechanism involving tau and ceruloplasmin (Cp)/APP (4). Iron
is then recirculated by apo-Tf (5).
of normal functions. Iron is also important to mitochondrial
functions, where it is incorporated into Fe–S clusters and heme
proteins (Hentze et al., 2004). The mechanism for mitochondrial
uptake has not been categorically conﬁrmed, though the two pro-
posed pathways involve either (i) diffusion of NTBI or (ii) direct
translocation of extracellular Fe2Tf via an endosomal pathway
(Horowitz and Greenamyre, 2010). Within the mitochondria, the
frataxin protein (implicated in Friedreich’s ataxia) is suggested
to act as a intramitochondrial iron chaperone (Richardson et al.,
2010).
The only known export pathway in mammalian cells is medi-
ated via ferroportin (Ganz, 2005). Ferroportin allows ferrous iron
to be transported out of the cell (Donovan et al., 2005), and this
process requires a ferroxidase to oxidize the ferrous iron to ferric,
so that Tf can bind the exported iron. In the brain, ferroportin has
been identiﬁed in both neurons (Abboud and Haile, 2000) and
astrocytes (Dringen et al., 2007), as have the corresponding fer-
roxidases, the amyloid precursor protein (APP; Duce et al., 2010)
and Cp (Texel et al., 2011).
REGULATION OF IRON-ASSOCIATED PROTEINS
Iron-associated proteins are regulated by iron status, therefore
form a cycle to regulate ironmetabolism (Figure 2). In cases of low
cellular iron, two iron regulatory proteins (IRP1/2) are free to bind
directly with iron responsive element (IRE) stem-loop structures
within the mRNA of iron-binding proteins. The 3′ untranslated
portion of, for example, TfR1 mRNA is sensitive to ribonuclease
degradation, thus binding with IRP1/2 protects the mRNA and
promotes TfR1 expression, increasing cellular iron uptake. Con-
versely, binding of IRP1/2 to the 5′ untranslated region (UTR) of,
for example, ferritin mRNA prevents translation, reducing cyto-
plasmic ferritin expression, reducing the iron storage capacity of
the cell, and increasing available iron (Aisen, 2001). When iron
levels in the cell are high, labile iron binds with IRP1/2, preventing
interactions between the regulatory proteins and the IREs in the
mRNA of various iron regulating proteins (see Figure 2), elicit-
ing the reverse cellular response to that observed in cases of iron
deﬁcit. The mechanism of iron-mediated inhibition of IRP/IRE
binding depends on the protein involved: IRP1–Fe undergoes a
conformational change that prevents IRE binding, whereas IRP2–
Fe complexes undergo degradation via the ubiquitin proteasome
pathway (Pantopoulos, 2004). Both IRP1 and IRP2 are present in
the rat (Siddappa et al., 2003) and human brain (Connor et al.,
1992c); IRP1 has been suggested as the primary regulatory protein
in the human brain and is capable of forming a double IRP1/IRE
complex (Hu and Connor, 1996).
Frontiers in Aging Neuroscience www.frontiersin.org July 2013 | Volume 5 | Article 34 | 3
“fnagi-05-00034” — 2013/7/16 — 20:30 — page 4 — #4
Hare et al. Iron metabolism and neurological diseases
FIGURE 2 | Factors influencing cellular iron metabolism. Cellular oxygen
homeostasis regulates iron metabolism in the nucleus via the hypoxia
inducible factors (HIF-1α and -1β). In normoxia conditions, Fe2+ mediates the
hydroxylation of proline residue 546 on HIF-1α by prolyl-4-hydroxylase (PHD),
which enables ubiquitination via binding with the von Hippel–Lindau tumor
suppressor gene product (VHL). Decreased HIF-1α inhibits transcription of
proteins dictating iron uptake and export. In the iron-deﬁcient cell, HIF-1α
instead interacts with CREB binding protein/p300 (CBP/p300) and forms a
heterodimer with HIF-1β, activating transcription of target genes possessing
hypoxia response elements. In the cytosol, the iron replete cell prevents the
binding of iron responsive proteins (IRP) -1 and -2 to the iron responsive
elements (IREs) in the 5′ and 3′ untranslated region (UTR) of mRNA, inhibiting
the transcription of uptake proteins and promoting expression of proteins
involved in iron export. In cases of iron deﬁciency, IRPs directly interact with
the 5′- and 3′-UTRs, eliciting the reverse effect. TfR, transferrin receptor;
DMT-1, divalent metal transporter-1; APP, amyloid precursor protein.
Ironmetabolism is also transcriptionally regulatedby the action
of hypoxia inducible factors (HIFs; see Figure 2), which consists
of a cytosolic protein (HIF-1α) and a nuclear HIF-1β subunit
that form a DNA binding heterodimer (Peyssonnaux et al., 2008).
HIF-1α levels are dictated by cellular chemistry, and in normal
conditions HIF-1α is hydroxylated by prolyl hydroxylase, marking
the adduct for ubiquitination and degradation (Ratcliffe et al.,
1999). This reaction requires oxygen, 2-oxoglutarate, ascorbate,
and iron as cofactors. In hypoxic conditions HIF-1α ubiquitina-
tion is inhibited and translocation to the nucleus is increased,
where dimerizationwithHIF-1β allows bindingwith cyclic adeno-
sine monophosphate (cAMP) response element-binding protein
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(CREB),which activates transcription of target genes with hypoxia
response elements (HREs; Semenza, 2000). As iron is necessary
for hydroxylation of HIF-1α, any decrease in cellular iron lev-
els will increase dimerization of HIF-1α and β and downstream
transcription of target genes, which, unsurprisingly, includes those
responsible for Tf (Rolfs et al., 1997), TfR1 (Lok and Ponka, 1999),
and DMT1 (Lis et al., 2005).
With such a sophisticated regulation mechanism for regulating
iron-associated proteins transcription and translation, it is sur-
prising diseases of iron overload and deﬁciencies exist. Some of
these disorders arise from nutritional deﬁciency/excess or genetic
mutation in one or more iron-associated proteins. But as will be
described, the disorders of iron metabolism are invariably chronic
disorders, not acute disorders. Possibly because there is complex
regulatory mechanism that can resist, and then compensate for,
short-term changes to iron levels.
IRON FLUX AND DEFICIENCY
Iron deﬁciency is amajor nutrition deﬁciencymost often observed
in the developing world. Even in a developed nation, such as the
USA, approximately 10% of toddlers and women of childbearing
age are iron-deﬁcient (Looker et al., 1997). As described above,
the cellular iron regulatory mechanism is nuanced and robust,
therefore allowing considerable divergence from the homeostatic
norm of iron levels before disease precipitates. Disorders of iron
homeostasis are thus invariably chronic, not acute diseases. This
is especially true of the brain, which has more stable iron levels
compared to the other organs (Youdim et al., 1989).
Peripheral iron deﬁciency can result in minor to severe symp-
toms. Anemia is an advanced iron deﬁciency syndrome caused by
a number of factors ranging from dietary deﬁciency, blood loss,
and metabolic lesions. The most common symptoms arising from
anemia result fromreducedoxygen transportationbyhemoglobin.
These symptoms include pallor, fatigue, faintness, shortness of
breath, muscle weakness, angina pain, and elevated cardiac out-
put (as compensation for reduced oxygen carrying capacity;Wood
and Elwood, 1966).
While symptoms of anemia can arise over a period of weeks
to months, iron in the brain is more resistant to dietary changes
(Youdim et al., 1989) and indeed the brain may have critical peri-
ods that determine the level of iron in the brain throughout life
(Dallman et al., 1975; Dallman and Spirito, 1977; Ben-Shachar
et al., 1986). The brain accumulates iron during the weaning
period,which establishes an iron“set point”for the brain. Perinatal
pups on a restricted iron diet cannot recover their brain iron levels
when supplemented later in life (Ben-Shachar et al., 1986). It has
been proposed that the brain of a post-weaned mammal is imper-
meable to peripheral iron (Kaur et al., 2007), possibly explaining
why brain iron levels are not easily altered with diet (Ben-Shachar
et al., 1986). However, supplementation of isotopically enriched
iron to mice reveals dietary iron incorporation into the brain at a
similar rate to other organs (Chen et al., 2013). Peripheral iron is
able to enter the brain by patterning with Tf, which can undergo
receptor-mediated transcytosis to pass through the BBB (Fishman
et al., 1987; Bradbury, 1997; Morgan and Moos, 2002). It is likely
that brain iron is in constant ﬂux with peripheral pools of iron.
We speculate that brain iron levels do not tangibly deviate from
the norm despite changes in the diet, because the brain iron lev-
els are strictly governed by the iron homeostatic mechanism, and
where the normal level of iron in the brain for an adult indi-
vidual is likely determined in the critical weaning period of the
mammal. This period can thus shape the iron biochemistry of
the brain throughout the life of an individual, highlighting the
urgency of addressing nutritional deﬁciency in infants raised in
areas of poverty. Described below, chronic brain iron deﬁciency
disrupts important process in the brain, altering neurochemistry
that eventually leads to disease.
NEUROCHEMICAL EFFECT OF IRON DEFICIENCY
NEUROTRANSMITTER SIGNALING
Iron affects synthesis and signaling of the neurotransmitters
dopamine, noradrenalin, adrenaline and 5-hydroxytryptamine,
which are involved in emotion, attention, reward, movement, and
various other functions. These neurotransmitters are synthesized
by a number of iron-dependent enzymes including phenylalanine
hydroxylase (Gottschall et al., 1982), tyrosine hydroxylase (Ramsey
et al., 1996), and tryptophan hydroxylase (Kuhn et al., 1980). Brain
iron deﬁciency (BID), however, rarely causes reduced expression
or activity of these enzymes (Youdim et al., 1989). The conser-
vation of iron in these enzymes under BID possibly reﬂects the
importance of these enzymes to brain function.
In addition to neurotransmitter synthesis, iron impacts several
other steps in neurotransmitter signaling, which are more vulner-
able to changes in iron levels. Reduced neuronal uptake of the
catecholaminergic neurotransmitters has been observed in several
BID models (Burhans et al., 2005; Beard et al., 2006b; Bianco et al.,
2008), and the extracellular concentration of neurotransmitters
are elevated in BID rats (Beard et al., 1994). Dopaminergic signal-
ing is further perturbed in iron deﬁciency by attenuating afﬁnity
and expression of D2 neurotransmitters (Youdim et al., 1989).
ENERGY PRODUCTION
The brain has a high energy demand, accounting for 20% of
basal oxygen consumption (Halliwell, 2006) and thus requires
high iron levels to generate ATP by the electron transport chain
in the mitochondria. Various mitochondrial enzymes utilize iron
as a cofactor including the mitochondrial ferredoxins (Redfearn
and King, 1964), cytochromes (Slater, 1949), and aconitase (Dick-
man and Cloutier, 1950). Iron deﬁciency changes mitochondria
morphology (Jarvis and Jacobs, 1974), impairs function (Masini
et al.,1994), anddamagesmitochondrialDNA(Walter et al.,2002).
Reduced mitochondrial efﬁciency possibly explains why iron deﬁ-
ciency results in elevation of oxidative stress markers (Knutson
et al., 2000; Jeong et al., 2011; Wan et al., 2012a), despite loss of
pro-oxidant iron.
MYELINATION
Myelin is the fatty“whitematter”that insulates axons andpreserves
their signaling. Accordingly, under basal conditions, oligoden-
drocytes exhibit high levels of iron comparative to other brain
cells (Benkovic and Connor, 1993; Connor et al., 1995). Iron
treatment to cultured glial restricted precursor cells increases
their differentiation into GalC1 oligodendrocytes, while treat-
ment to culturedO2Aoligodendrocytes progenitors increases their
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proliferation without altering differentiation (Morath and Mayer-
Proschel, 2001). Iron, therefore, has marked, but distinct effects
on the temporal sequence of oligodendrocyte development. In
a rat model, BID restricts both glia precursor cell proliferation
and differentiation into oligodendrocytes (Morath et al., 2002)
and decreases components of myelin: myelin basic protein,myelin
proteolipid protein, galactolipids, phospholipids, and cholesterol
(Yu et al., 1986; Ortiz et al., 2004). Lack of myelination causes
slower neuronal conduction, evidenced by retardation of reﬂexes.
In humans, iron deﬁciency is associated with abnormal reﬂexes in
infants (Armony-Sivan et al., 2004) and in iron-deﬁcient children,
deﬁcits in auditory brain stem potentials and visual evoked poten-
tials have been observed (Roncagliolo et al., 1998; Algarin et al.,
2003).
NEUROLOGICAL DISORDERS ASSOCIATED WITH IRON
DEFICIENCY
FAILURE TO THRIVE
It is now widely recognized that BID in early life is associated with
developmental delays in various brain faculties. Iron deﬁciency,
characterized by anemia, has been associated with poorer ﬁne and
gross motor skills, visual-motor integration, language and global
IQ, accompanying higher scores in anxiety and depression, social
and attention problems (Palti et al., 1985; Lozoff et al., 1991; Hur-
tado et al., 1999) with some symptoms persisting 10 years after
treatment for anemia (Lozoff et al., 2000). While the association
between iron and various markers of developmental delay are
unequivocal, the causal relationship is complicated by confound-
ing socioeconomic variables that often accompany iron deﬁciency
including generally poor nutrition, lack of stimulation in the
home, lack of maternal warmth, poor maternal education, mater-
nal depression, more absent fathers, parasitic infection, and low
birth weight (Grantham-McGregor and Ani, 2001).
The importance of iron to neurodevelopment is thus unclear
from observational human studies, which has necessitated study
of iron-deﬁcient experimental animal models. Agreeing with
complementary human studies, BID in rats causes delayed behav-
ioral milestones (Beard et al., 2006a), including impaired memory
(Yehuda et al., 1986; Wachs et al., 2005) and motor function (Hunt
et al., 1994). Symptoms resulting from dietary iron restriction in
the ﬁrst 21 days of the life of the rat are not recoverable even after
6 weeks of iron supplementation (Ben-Shachar et al., 1986). Com-
bining thehumanandanimal evidences strongly supports a critical
role for iron in neurodevelopment, and since the symptoms are not
readily correctable after the critical period, these also highlight the
importance of monitoring and early dietary intervention.
ATTENTION DEFICIT HYPERACTIVITY DISORDER
Attention deﬁcit hyperactivity disorder (ADHD) is a developmen-
tal disordermanifesting in symptoms of inattention, hyperactivity,
and impulsiveness. ADHD is highly heritable, and several candi-
date disease-causing genes are involved in dopamine neurotrans-
mission (DAT1, DRD4, DRD5; Elia and Devoto, 2007). Since iron
interacts with multiple steps in dopamine neurotransmission, it
is possible that BID might precipitate ADHD in idiopathic cases.
While several studies showed reduced ferritin in children affected
by ADHD (Konofal et al., 2004; Oner et al., 2008; Cortese et al.,
2009; Juneja et al., 2010; Menegassi et al., 2010), the largest study
(194 children), reported unaltered serum ferritin levels between
ADHD patients and controls (Donfrancesco et al., 2012). As pre-
viously mentioned, iron status in children often co varies with
multiple parameters of socioeconomic status, which might con-
found these studies. Further peripheral markers of iron do not
often reﬂect the status of brain iron; therefore peripheral iron is
not likely altered inADHD.However, a recent study of 36 individu-
als reported reduced brain iron in the thalamic region as measured
bymagnetic resonance imaging (MRI) inADHDpatients (Cortese
et al., 2012) suggesting a role for BID in the pathogenesis of this
disease.
Could iron supplementation therefore be used as a treatment
for ADHD? A case study reported a 3 year-old presenting with low
serum ferritin (13 ng mL−1) accompanying ADHD who was sup-
plemented with ferrous sulfate (80 mg day−1) and 8 months later
was observed to exhibit various behavioral improvements (Kono-
fal et al., 2005). This prompted a 12-week clinical trial of iron
supplementation in ADHD, which recorded improvements in the
ADHD rating scale for the treatment group (Konofal et al., 2008).
These studies warrant further investigation into iron as a potential
therapeutic, however, as discussed above, iron supplementation
after a critical period is not effective in reversing cognitive symp-
toms of early BID in rats (Ben-Shachar et al., 1986), which might
limit the use of this approach in ADHD.
RESTLESS LEGS SYNDROME
Restless legs syndrome (RLS) is a neurological disorder charac-
terized by uncomfortable or odd sensations in the body (often
legs) that prompt an incessant urge to move (Earley, 2003). The
prevalence of RLS is estimated to be between 5 and 10% of
the population (Lavigne and Montplaisir, 1994; Rothdach et al.,
2000; Ulfberg et al., 2001). The disorder is associated with reduced
dopamine uptake and reduced D2 receptor density (Staedt et al.,
1995; Turjanski et al., 1999; Michaud et al., 2002), and is often
treated with dopamine-based therapies (Hening et al., 1999; Allen
et al., 2001). This neurochemical proﬁle is consistent with BID
(Youdim et al., 1989) of the nigrostriatal pathway. Indeed low fer-
ritin and high Tf levels have been reported in CSF of RLS patients,
while serum indices of iron metabolism were not altered (Earley
et al., 2000; Clardy et al., 2006). Direct measurements of iron by
post-mortem histological staining (Connor et al., 2003) and MRI
(Allen et al., 2001; Earley et al., 2006) reveal decreased levels in the
substantia nigra (SN) of affected patients.
NEURODEGENERATION
What are the lifetime consequences of BID?This remains anunder-
explored subject in brain iron research, which has historically
focused on BID in neurodevelopment, and iron accumulation
in neurodegeneration. Accordingly, to our knowledge, there has
been no report of BID in a neurodegenerative disorder. Recently, a
genetic mouse model of motor neuron iron deﬁciency (IRP2−/−)
exhibited reduced mitochondrial activity, hypomyelination, and
neurodegeneration (Jeong et al., 2011), raising the possibility of
BID-induced neurodegenerative disorders. Patients with the neu-
rodegenerative disorder, dementia with Lewy bodies (DLB), have
a threefold higher incidence of self-reported history of ADHD
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symptoms. However, the status of iron in ADHD patients is only
beginning to emerge, and the status of iron in DLB is also not
known, so it is premature to mechanistically connect the two
diseases via iron. Low iron levels impair mitochondrial func-
tion (Masini et al., 1994), and increase oxidative stress markers
(Knutson et al., 2000), possibly by limiting the functionof the iron-
dependent antioxidant, catalase (Wan et al., 2012a). Longer-term
studies of rodent models of BID will illuminate the neuroanatom-
ical and neurobiochemical changes that result from low iron
bioavailability.
IRON ACCUMULATION IN THE BRAIN
The sophisticated mechanisms that manage iron in the brain high-
light the need for tightly controlled iron regulation, in order to
exploit its utility in cellular operations, while preventing its dele-
terious capacity. Functional loss of IRPs by genetic mutations
induces brain irondeposition,which is sufﬁcient to causeneurode-
generation in diseases like aceruloplasminemia (Miyajima et al.,
1987; Hochstrasser et al., 2004) and neuroferritinopathy (Feyt
et al., 2001; Chinnery et al., 2007). This demonstrates the potential
for iron elevation to participate in neuronal loss of more common
neurodegenerative diseases [e.g., Alzheimer’s (AD) and Parkin-
son’s disease (PD)] where brain iron elevation features in both
diseases.
BRAIN IRON ACCUMULATION WITH AGING
Aging is an important risk factor for neurodegenerative diseases.
Multiple failures of the iron regulatory system in disease could be
contributed to by the aging process (Bartzokis et al., 1997; Martin
et al., 1998; Pfefferbaum et al., 2009; Penke et al., 2012; Daugherty
and Raz, 2013). Age-related iron retention can serve as predictors
of behavioral deﬁcits, such as cognitive decline (Penke et al., 2012)
and motor impairment (Cass et al., 2007; Kastman et al., 2012),
highlighting the possibility of its involvement in age-associated
decline.
Brain iron elevation with age could be contributed to by
changes in various proteins that comprise the iron regulation
machinery. Ferritin is elevated during the aging process in both
gray and white matter of occipital cortex (Connor et al., 1992b)
and the SN (Zecca et al., 2004), but is unchanged in motor cortex
and superior temporal gyrus (Connor et al., 1992b). Tf expression
was found to be decreased in white matter of superior temporal
gyrus, but elevated in white matter of occipital cortex (Connor
et al., 1992b). Cp was found to be elevated in gray matter with
aging,without changes inwhitematter (Connor et al., 1993), while
another report observed that Cp was unchanged in SN (Zecca
et al., 2004). In rat brains, iron and ferritin were found to increase
with age, while Tf levels remain unchanged (Roskams and Con-
nor, 1994). The mechanism of age-related iron accumulation is
only beginning to be elucidated. The selective vulnerability of iron
accumulation during aging could also explain why iron elevation
is a feature of various neurodegenerative diseases.
ALZHEIMER’S DISEASE
Alzheimer’s disease is the most prevalent neurodegenerative
disease characterized clinically by progressive dementia, and
pathologically by the presence of Aβ-containing plaques, and
tau-containing neuroﬁbrillary tangles in affected brain areas. Ele-
vated iron is also a feature of AD-effected post-mortem brains
(Zhu et al., 2009; Duce et al., 2010; Smith et al., 2010; Qin et al.,
2011;Antharamet al., 2012; Loef andWalach,2012). Iron accumu-
lation occurs in AD cortex and hippocampus, but not cerebellum
(Andrasi et al., 1995; Duce et al., 2010; Antharam et al., 2012), con-
sistent with the pathological proﬁle of neurodegeneration in AD.
In addition, iron is accumulated in both plaques and tangles (Con-
nor et al., 1992a; Smith et al., 1997; Meadowcroft et al., 2009), and
is estimated to be three times that of the normal neuropil level in
plaques (Lovell et al., 1998). The iron content in hippocampus of
patients with AD was reported to correlate with the mini-mental
state examination (MMSE) and the disease duration (Ding et al.,
2009; Zhu et al., 2009), suggesting that iron can play a signiﬁcant
role in the disease progression.
Several genes of iron regulatory proteins are risk factors for
sporadic AD, including Tf and human hemochromatosis protein
(HFE). In a genome-wide association study (GWAS) study, Tf
variant C2 positively correlates with AD risk with an OR of 1.21
(Bertram and Tanzi, 2008), which is supported by a number of
independent studies (Van Landeghem et al., 1998; Schjeide et al.,
2009; Kauwe et al., 2010) but was not conﬁrmed in a recent large-
scale GWAS study (Hollingworth et al., 2011). In addition, HFE
mutations (H63DandC82Y) are risk factors forAD independently
(Sampietro et al., 2001; Blazquez et al., 2007), and synergistically
with APOE gene (Kauwe et al., 2010; Giambattistelli et al., 2011;
Lehmann et al., 2012). Both of the genes are also shown to mod-
ulate iron content, and are implicated in the risk of cognitive
impairment in normal aging (Bartzokis et al., 2011).
Iron accumulation can promote aggregation of both Aβ and
tau, the key proteins involved in plaque and tangle formation,
respectively. Three histidine residues of Aβ were suggested as the
binding amino acids of iron, and this complex is redox-active
(Nakamura et al., 2007; Bousejra-ElGarah et al., 2011). Recently
it was found that iron delayed the amyloid ﬁbril formation but
enhanced the toxicity in vitro, suggesting the iron-bound Aβ
oligomer could serve as a toxic species (Mantyh et al., 1993; Schu-
bert and Chevion, 1995; Liu et al., 2011). These observations are
relevant to disease since iron is concentrated in plaques (Mead-
owcroft et al., 2009; Gallagher et al., 2012), and increased iron
content is prior to plaque formation in an animal model of AD
(Leskovjan et al., 2011). Aβ–iron complex can induce ROS via
Fenton chemistry (Rottkamp et al., 2001; Rival et al., 2009), and
activate B-cell lymphoma 2 (Bcl-2) apoptosis pathway (Kuperstein
and Yavin, 2003). Chelation of iron can prevent Aβ aggregation,
and reverse the consequent memory loss in animal models of AD
(Huang et al., 2004; Guo et al., 2013b).
Iron and tangles co-localized in AD (Smith et al., 1997) and
tangles can bind iron in a redox-dependent manner, acting as
a source for ROS within the neurons (Smith et al., 1997; Sayre
et al., 2000). This process can also be removed by iron chelation
(Shin et al., 2003). Fe(III), but not Fe(II), can induce tau aggre-
gation in vitro, which again can be reversed by reducing Fe(III)
to Fe(II) (Yamamoto et al., 2002) or iron chelators (Amit et al.,
2008). Fe(II) can induce tau hyperphosphorylation (Lovell et al.,
2004; Chan and Shea, 2006), via activation of extracellular signal-
regulated kinase 1/2 (Erk1/2) pathway or the mitogen-activated
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protein kinase (MAPK) pathway (Muñoz et al., 2006; Huang et al.,
2007). Chelation therapies such as deferoxamine can inhibit iron-
induced tau hyperphosphorylation in vivo (Guo et al., 2013a), and
prevention of iron uptake can also inhibit this event by deacti-
vating glycogen synthase kinase 3 (GSK-3) and cyclin-dependent
kinase 5 (Cdk-5; Xie et al., 2012), two key tau kinases (Lei et al.,
2011).
Understanding the cause of iron accumulation in AD might
lead to new therapeutic opportunities. Multiple components of
the iron regulatory system are altered inAD including IRP2 (Smith
et al., 1998), ferritin (Connor et al., 1992a), and Tf (Loefﬂer et al.,
1995). Of particular interest is APP, which is involved in Aβ pro-
duction and iron homeostasis. APP expression is unchanged in
AD cortex but its ferroxidase activity was reported to be decreased
(Duce et al., 2010). This could prevent ferroportin-mediated iron
export and Tf loading, which would lead to iron retention within
neurons. APP-mediated iron export is also impacted by AD-
associated tau protein (Lei et al., 2012). Soluble tau levels are
reduced inAD brains compared to control brains (Ksiezak-Reding
et al., 1988; Shin et al., 1992; Khatoon et al., 1994; Zhukareva et al.,
2001, 2003; van Eersel et al., 2009); which might result from tau
deposition into insoluble aggregates during the disease progress
(Khatoon et al., 1994). Loss of functional tau could further per-
turb APP-mediated iron export by restricting the presentation of
APP at the surface.
PARKINSON’S DISEASE
Parkinson’s disease is the most prevalent movement disorder,
caused by loss of dopaminergic neurons in the SN pars compacta.
The brain of PD patients, and especially the SN, is decorated by
Lewy body inclusions that are enriched with the α-synuclein pro-
tein. As early as 1924, iron deposition in the SN of PD patients
was described (Lhermitte et al., 1924). Iron elevation within this
nucleus has been consistently reported using multiple techniques
such as inductively coupled plasma-mass spectrometry (ICPMS;
Dexter et al., 1989; Lei et al., 2012), atomic absorption spec-
troscopy (Ayton et al., 2012b), X-ray ﬂuorescence (Popescu et al.,
2009), and MRI (Bartzokis et al., 1999).
Iron deposits have been found in Lewy Bodies in PD cases
(Castellani et al., 2000), suggesting that α-synuclein may inter-
act with iron at the biochemical level. Indeed, iron binds to
α-synuclein (Bharathi andRao, 2008; Peng et al., 2010), accelerates
α-synuclein aggregation (Golts et al., 2002; Kostka et al., 2008),
and causes toxic hydroxyl radical production in vitro (Turnbull
et al., 2001). Treating iron to cells initiates α-synuclein aggre-
gation (Ostrerova-Golts et al., 2000; Gault et al., 2010; Li et al.,
2011), and the resultant oligomer promoted α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA)-receptor-mediated
excitotoxicity (Huls et al., 2011). Iron administration to cells that
overexpress a disease-related mutant form of α-synuclein, A53T,
enhanced cytotoxicity of the protein via increasing the autophagic
activity (Ostrerova-Golts et al., 2000; Chew et al., 2011), which
could explain how iron causes toxicity in PD.
Iron content in SN is a risk factor and may serve as a biomarker
of PD. Mutations in a number of iron-related proteins have been
shown to associate with the risk of PD, including Tf (Borie et al.,
2002), IRP2 (Deplazes et al., 2004), ferritin (Foglieni et al., 2007),
and DMT1 (He et al., 2011). It has been debated whether iron
accumulation in SN is a secondary effect of cell death in PD. How-
ever, recent developments in MRI and transcranial sonography
(TCS) makes it possible to examine brain iron content in living
patients. It has been shown using MRI that iron accumulates at
the early stage of PD before the symptom onset (Bartzokis et al.,
1999; Martin et al., 2008), and healthy individuals with increased
SN iron content determined by TCS had 17 times higher risk of
developing PD (Berg et al., 2011). The SN iron elevation in PD
patients, shown by MRI, correlates with the disease susceptibility
(Baudrexel et al., 2010), severity (Atasoy et al., 2004; Wallis et al.,
2008) and duration of the disease (Kosta et al., 2006; Zhang et al.,
2010). The early rise in iron, measured by TCS and MRI supports
a role for iron in the pathogenicity of PD.
Iron accumulation is alone sufﬁcient to cause parkinsonian
neurodegeneration. Direct iron injection to rat brains can cause
SN neuron loss (Ben-Shachar and Youdim, 1991), and feeding
neonatal mice with iron can trigger later life parkinsonism and
nigral degeneration (Kaur et al., 2007). Diseases primarily charac-
terized by brain iron accumulation, including aceruloplasminemia
(Miyajima et al., 1987; Hochstrasser et al., 2004; McNeill et al.,
2008), neuroferritinopathy (Crompton et al., 2002; Chinnery et al.,
2007), and iron accumulation (NBIA) (Schneider et al., 2012),
often cause symptoms of PD. The observations from these dis-
eases which are caused by rare loss-of-function mutations of IRPs
indicate that a similar iron accumulation observed in idiopathic
PD likely participates in the degenerative processes. Aceruloplas-
minemia can be recapitulated in mice that lack the Cp gene, and
this can be rescued with iron chelation (Patel et al., 2002; Ayton
et al., 2012b).
Modulation of iron shows beneﬁcial effects on PD ani-
mal models. PD toxin model, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) or 6-hydroxydopamine (6-OHDA)
cause SN iron accumulation inmice, coincident with neuronal loss
(Hare et al., 2013). These PD models can be rescued by iron chela-
tion (Kaur et al., 2003; Mandel et al., 2004; Youdim et al., 2004a,b).
Iron-mediated toxicity in these models can also be ameliorated by
genetic or pharmacologically restoring ferritin (Kaur et al., 2003)
and Cp (Ayton et al., 2012b).
Why does iron accumulate in PD? This could be contributed
by a number of iron-related proteins that are changed in PD. Fer-
ritin levels have been found to be decreased in post-mortem PD
brains (Dexter et al., 1990; Werner et al., 2008); loss of iron stor-
age capacity potentially makes free iron species more available for
toxic interactions. Iron accumulation in PD might be caused by
increased neuronal iron import. DMT1 is elevated in SN of PD
patients (Salazar et al., 2008), which could promote iron import,
but the levels of TfR1, which is required for DMT1-mediated iron
import are unchanged when corrected for neuronal loss (Mash
et al., 1991; Morris et al., 1994; Faucheux et al., 1997). Alterna-
tively, iron accumulation in PD could also be attributed to reduced
iron export. Cp levels in PD brains were unaltered, however, the
activity is selectively reduced in SN, which could bottleneck iron
export (Ayton et al., 2012b). Tau protein is also implicated in PD
(Lei et al., 2010), and selective reduction of tau found in SN of PD
patients may also contribute to iron accumulation by preventing
APP-mediated iron export (Lei et al., 2012).
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OTHER NEUROLOGICAL DISORDERS
Iron accumulation has been observed in affected brain regions
of various diseases including progressive supranuclear palsy (Cof-
fey et al., 1989; Dexter et al., 1991; Boelmans et al., 2012), Pick’s
disease (Ehmann et al., 1984), Huntington’s disease (Dexter et al.,
1991; Bartzokis et al., 2007; Jurgens et al., 2010; Rosas et al., 2012),
prion disorders (Singh et al., 2009a, 2012), amyotrophic lateral
sclerosis (Oba et al., 1993; Santillo et al., 2009; Langkammer et al.,
2010), and multiple system atrophy with striatonigral degenera-
tion (Dexter et al., 1991; Vymazal et al., 1999; von Lewinski et al.,
2007;Wang et al., 2012). The iron accumulation in diseases such as
prion disorders and Huntington’s disease may result from ferritin
accumulation (Simmons et al., 2007; Singh et al., 2012), but the
cause or implications of iron elevation for these diseases is unclear
at this stage.
Friedreich’s ataxia is a disorder of iron metabolism more
extensively studied. This autosomal recessive degenerative dis-
ease results from mutations in the mitochondrial protein frataxin
(Campuzano et al., 1996; Carvajal et al., 1996). Friedreich’s ataxia
is characterized by degeneration of large sensory neurons and
cardiomyopathy (Gordon, 2000), but brain atrophy and iron accu-
mulation are also features of the disease (Synofzik et al., 2011).
Recent studies suggested that the function of frataxin is related
to the maintenance of iron homeostasis, acting as iron-storage
protein in mitochondrial similar to ferritin, and also an intrami-
tochondrial iron chaperone. It is also suggested to be involved in
heme and iron sulfur cluster biogenesis. The frataxin mutant is
unstable and severe reduction of the protein results in intramito-
chondrial iron accumulation and cytosolic iron deﬁciency in mice
and humans, and is suggested to contribute to the pathogene-
sis of the disease (Gordon, 2000; Puccio et al., 2001; Richardson
et al., 2010). Interestingly, a high iron diet limits some of the phe-
notypes in mouse models such as cardiac hypertrophy (Whitnall
et al., 2012).
Like iron, copper also participates in neurodegenerative path-
ways. Copper is able to cause the aggregation of alpha synuclein
(Bharathi and Rao, 2008), and copper is a co-factor of dopamine
beta-hydroxylase, which is involved in dopamine synthesis (Ash
et al., 1984). Copper is decreased in PD SN (Dexter et al., 1991;
Ayton et al., 2012b) which might be a reason why the copper-
dependent Cp protein is dysfunctional in the disease. Peripheral
Cp is also depleted in Wilson’s disease, which is primarily a disor-
der of copper homeostasis, caused by a genetic mutation to ATP7b
(Bull et al., 1993). Copper accumulates in liver and brain, along
with iron (Shiono et al., 2001; Litwin et al., 2013). Why does iron
also accumulate as a result of the disease? Possibly reduced Cp lev-
els in plasma reduce iron export in liver and brain, resulting in iron
accumulation. Whatever the mechanism, Wilson’s disease often
presents as early-onset PD, possibly mediated by the elevation of
copper and iron (Machado et al., 2006).
TOXICITY MECHANISMS OF IRON OVERLOAD IN DISEASES
Iron can induce neurotoxicity by its ability to promote the
formation of ROS, a source of oxidative stress. Elevated iron
is potentially neurotoxic, indeed the direct injection of iron
into the rat brain causes neurodegeneration (Ben-Shachar and
Youdim, 1991), possibly via an oxidative stress pathway which
initiates several apoptotic signaling pathways (Ke and Ming Qian,
2003).
Recently, a type of RAS-related cell death pathwaywas shown to
be linked with intracellular iron levels, termed ferroptosis (Dixon
et al., 2012), which could be potentially responsible for cell death
seen in iron overload diseases. This type of cell death pathway
shared no markers of apoptosis (e.g., caspase activation, mito-
chondrial cytochrome c release), but could be prevented by iron
chelation or iron uptake inhibition (Yagoda et al., 2007; Yang and
Stockwell, 2008). This pathway is not induced by Fenton chem-
istry; rather it is related with iron-dependent enzymatic activities
(Dixon et al., 2012). Indeed, inappropriate intracellular iron accu-
mulation potentially damages a number of proteins such as
Ca2+-ATPase (Kaplan et al., 1997; Moreau et al., 1998), glutamate
transporter (Gnana-Prakasam et al., 2009; Yu et al., 2009; Mitchell
et al., 2011),Na+/K+-ATPase (Kaplan et al., 1997; Strugatsky et al.,
2003), and N-methyl-D-aspartate (NMDA) receptor (Nakamichi
et al., 2002; Munoz et al., 2011), as well as oxidizes lipid such as
cholesterol (Kraml et al., 2005; Graham et al., 2010; Shinkyo and
Guengerich, 2011), ceramides (Yurkova et al., 2005), and sphin-
gomyelin (Jenkins and Kramer, 1988; Isaac et al., 2006); all of
which were proposed to ultimately cause synaptic dysfunction and
neuronal cell death (Mattson, 2004).
It is therefore not surprising that iron elevation observed in
a number of neurodegenerative diseases, such as AD and PD, is
proposed to be a key mediator in cell loss of these diseases (Ayton
et al., 2012a; Lei et al., 2012). In neurodegenerative diseases, iron
is also found to partner with disease-related proteins, such as β-
amyloid, tau, prion, and α-synuclein, which form soluble and
insoluble aggregates and activate cell death pathways (Chiti and
Dobson, 2006). The presence of iron accelerates the aggregation
process in vitro (Schubert and Chevion, 1995; Ostrerova-Golts
et al., 2000; Rottkamp et al., 2001; Yamamoto et al., 2002; Khan
et al., 2006), and aggravates the oxidative stress induced by the
protein in vivo (Huls et al., 2011; Li et al., 2011; Wan et al., 2011).
Recently it has emerged that these disease-related proteins also
participate in iron metabolism. The mRNA of APP has an IRE in
its 5′-UTR (Rogers et al., 2002, 2008), and was found to facilitate
iron export in vitro and in vivo (Duce et al., 2010). Suppression
of APP expression in mice resulted in age-dependent iron accu-
mulation (Duce et al., 2010), and overexpression of wild type
APP resulted in iron reduction in SH-SY5Y neuroblastoma cells
(Wan et al., 2012b). Interestingly, overexpression of a disease-
related mutant form of APP, the Swedish mutant, in SH-SY5Y
cells and Caenorhabditis elegans causes signiﬁcant iron retention
accompanied with elevated ROS (Wan et al., 2011). It was pro-
posed by the authors that the observed iron change is due to the
increased amount of Aβ (Wan et al., 2011), however, it can be alter-
natively explained by loss-of-APP function. Aβ oligomers were
shown todecreaseNTBIuptake, however, thedisease relevancewas
unclear (SanMartin et al., 2012). Recently, tau protein was found
to mediate APP trafﬁcking, and reduction of tau blocked iron
export, leading to intracellular iron accumulation (Lei et al., 2012).
Tau knockout mice exhibited age-dependent neurodegeneration,
which could be pharmacologically prevented by iron chelation
therapy (Lei et al., 2012), supporting a function of tau in iron
metabolism.
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Other disease related proteins have been investigated less for
their association with iron metabolism, but the emerging data
could point to a role for these proteins in iron homeostasis. α-
synuclein exhibits an IRE in its 5′-UTR mRNA (Friedlich et al.,
2007), and is reported to be ferrireductase of unknown biologi-
cal function (Davies et al., 2011). Recently, prion protein was also
suggested to act as a functional ferrireductase, to modulate cellu-
lar iron uptake (Singh et al., 2009c, 2013). Loss of prion protein
caused irondeﬁciency inmice,which canbe reversed by expression
of wild type prion protein (Singh et al., 2009b). In addition, hunt-
ingtin protein, involved in Huntington’s disease, was also reported
as an iron-responsive protein (Hilditch-Maguire et al., 2000). In
huntingtin-deﬁcient zebraﬁsh, iron starvation was identiﬁed dur-
ing development, and these zebraﬁsh had decreased hemoglobin
production (Lumsden et al., 2007).
THERAPEUTICS BASED ON IRON MODULATION
Since iron involves the pathogenesis of neurodegenerative disor-
ders, chelation of iron therefore could be a therapeutic strategy.
Currently, iron chelation is utilized in practice for transfusional
iron overload and hemochromatosis (Nick, 2007). Treatment
for this type of diseases requires selective iron chelators with
high afﬁnity, to facilitate bulk excretion of iron from the body
(Positano et al., 2009; Meloni et al., 2010; Murphy and Oudit,
2010; Pietrangelo, 2010). Deferoxamine (Propper et al., 1976),
deferiprone (Kontoghiorghes et al., 1987a,b) and deferasirox (Piga
et al., 2006; Shashaty et al., 2006) have been tested for these dis-
eases. However, neurodegenerative diseases that feature regional
iron accumulation require therapeutic agents to cross blood–brain
barrier, and target speciﬁc brain regions in preference to the rest
of the body.
Several brain permeable iron chelators have been explored in
pre-clinical models of AD and PD (Kontoghiorghes et al., 1987a;
Ben-Shachar et al., 1992; Kaur et al., 2003; Youdim et al., 2004a;
Liang et al., 2008; Gogoi et al., 2011) although none of these
compounds have entered clinical trials so far. One pilot trial of
deferiprone was reported to be beneﬁcial for NBIA (Abbruzzese
et al., 2011). The mechanisms for neuroprotection effects of iron
chelators have been linked with suppression of apoptotic path-
way (Youdim et al., 2005; Avramovich-Tirosh et al., 2007; Zhu
et al., 2007; Amit et al., 2008; Gal et al., 2010), promoting sur-
vival pathways (Avramovich-Tirosh et al., 2010; Reznichenko et al.,
2010), restoration of protein degradation (Zhu et al., 2007), and
stabilization of mitochondrial function (Youdim et al., 2005).
Clioquinol is a moderate afﬁnity iron chelator that has under-
gone extensive pre-clinical testing for neurodegenerative disorders,
and a clinical trial (Cherny et al., 2001; Kaur et al., 2003; Ritchie
et al., 2003; Lei et al., 2012). The therapeutic effects of clioquinol
have often been attributed to its ionophore activity, which redis-
tributes copper and zinc into the cell (Cherny et al., 2001; Nitzan
et al., 2003; Adlard et al., 2008; Li et al., 2010; Crouch et al., 2011;
Park et al., 2011). However, its ability to chelate iron is also likely
involved in its neuroprotective properties. Iron binds to clio-
quinol (Tamura et al., 1973; Kidani et al., 1974; Ohtsuka et al.,
1982), and several beneﬁcial effects of clioquinol have reported
to be iron-dependent (Felkai et al., 1999; Atamna and Frey, 2004;
Choi et al., 2006; Rival et al., 2009). Treatment with clioquinol pre-
vents the elevation of SN iron levels in MPTP-treated mice, which
confers neuroprotection (Kaur et al., 2003). Similar treatment
also prevented age-related nigra degeneration in tau knockout
mice (Lei et al., 2012), highlighting a potential use of clioquinol
as an iron-binding agent. These results suggest that clioquinol
participates in iron redistribution, but more data is needed to
conﬁrm.
CONCLUSION
The tightly regulated nature of iron in the human brain protects
against diseases associated with excess or deﬁciency. Disease man-
ifests when these systems deteriorate or are overwhelmed. Iron
deﬁciency is prevalent, particularly in underdeveloped societies,
and causes long-term consequences to brain health. There is there-
fore urgent need to address nutritional deﬁciency inpregnancy and
in infancy to prevent these long-term consequences. Iron elevation
in the brain is a feature of several major neurodegenerative disor-
ders. While the cause of this is unknown, it is noteworthy that a
variety of neurodegenerative disease-associated proteins involved
in iron metabolism through various mechanisms, supporting the
hypothesis that iron and disease-related proteins participate in a
toxic cycle. The involvement of iron in neurodegenerative diseases
needs further elucidation, but iron overload in these disorders rep-
resents an attractive pharmacological target for disease modifying
therapies.
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